Q32 Bio Reports Favorable Phase 2a Trial Outcomes for Alopecia Areata Treatment

AI-generated NewsSnap summary based on source reporting.
Published: 2026-07-13T11:43:14Z
Category: business
Source: SEC.gov
Original source

Q32 Bio Inc. has announced positive 36-week results from Part B of its SIGNAL-AA Phase 2a clinical trial. The study evaluated bempikibart as a potential treatment for patients with severe or very severe alopecia areata. This development indicates promising progress in addressing the autoimmune condition, as detailed in a recent regulatory filing.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai